Global Point of Care Testing Market By Diagnostics Segment, By Mode, By Platform, By End User, By Region, Trends, Recent Developments, Company Profiles - Forecast to 2031

The global point of care testing (POCT) market is predicted to reach US$ 79.30 Billion by 2031, from US$ 44.24 Billion in 2023. The demand for point-of-care testing is increasing across the globe, backed by the increasing introduction of transportable, portable, and handheld instruments that have resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics. The rising incidence of infectious diseases and chronic conditions such as cardiovascular diseases and diabetes have stimulated the demand for point-of-care testing services. Infectious diseases are one of the primary causes of mortality globally, as they claim approximately 17 million lives annually, making up around 30% of the 56 million deaths recorded worldwide. As per statistics of the International Diabetes Federation, in 2021, approximately 537 million adults (20-79 years) are living with diabetes globally, and it is estimated to reach 643 million by 2030 and 783 million by 2045. Hence, the growing incidence of infectious diseases and chronic conditions will drive the point-of-care testing market growth over the forecast period. 
 
Besides, manufacturers in the POCT market are focusing on developing novel technologies for maximum testing within a minimum period. For instance, in February 2024, Abbott Laboratories secured regulatory approval from the FDA for its Binx Now COVID-19 & Flu A/B test. This point-of-care test can concurrently identify COVID-19, influenza A, and influenza B viruses, providing a more comprehensive diagnosis for respiratory infections at the point of care. Earlier, Abbott introduced ID NOW, the world's quickest molecular POC test, which provides COVID-19 findings in 13 minutes and is usable in a variety of decentralized healthcare settings such as doctors' offices and urgent care clinics. 

Recent Developments

• In June 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization for its cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, an automated multiplex real-time polymerase chain reaction (RT-PCR) assay on the cobas liat system.
• In December 2023, QIAGEN AV introduced the QIAcube Connect, a novel automated sample-to-result PCR platform tailored for point-of-care settings. The primary goal of this platform is to furnish swift and precise molecular diagnostic outcomes in closer proximity to patients.
• In June 2023, Sysmex Corporation launched a point-of-care testing system for rapid detection of antimicrobial susceptibility in Europe using a unique and proprietary microfluidic technology.

By Diagnostics Segment: Global Point of Care Testing Market & Forecast - Key Takeaways

• Based on the diagnostics segment, the blood glucose testing segment held the majority share of the global point-of-care testing market. Increasing usage of home-based glucose monitoring systems is one of the key trends observed in the point-of-care diagnostics industry. In recent times, there has been increased use of blood glucose testing due to the growing geriatric population, rising obese population, increasing lifestyle associated diseases, and increasing prevalence of diabetes. 
• Cardiac marker segment is expected to grow at a significant rate over the forecast period. The growing prevalence of cardiovascular ailments, increasing purchasing power, rise in the geriatric population, associated with high susceptibility to chronic diseases related to cardiac disorders, and economic diagnosis of chronic diseases in rural areas are expected to drive the market for cardiac markers. 
• Infectious diseases are the primary cause of mortality as they claim approximately 17 million lives annually, making up around 30% of the 56 million deaths recorded worldwide. Infectious disease testing has shifted from centralized to decentralized POC testing, resulting in better patient care. For instance, Abbott has introduced ID NOW, the world's quickest molecular POC test, which provides COVID-19 findings in 13 minutes and is usable in a variety of decentralized healthcare settings.

By Mode: Global Point of Care Testing Market & Forecast - Key Takeaways

• Based on mode, the point-of-care testing market is dominated by the OTC-based testing segment, as these tests are cost-effective as well as easily operative in nature. OTC tests do not require dedicated space as clinical laboratories, and even their turnaround time is quick. 
• The Prescription based testing segment is expected to grow at the highest rate over the forecast period. 

By Platform: Global Point of Care Testing Market & Forecast - Key Takeaways

• By platform, the Lateral Flow Assays (LFA) segment accounted for the largest revenue share in 2023. Lateral flow assays are simple devices used to detect the presence or absence of target analytes in samples. In the past few years, the POC diagnostics market for LFA has grown significantly due to the increasing adoption of LFA testing products in home care settings.
• The point-of-care testing market for immunoassays technology is expected to witness significant growth over the forecast timeframe. Rapid immunoassays improve the quality of care through their performance at point of care facilities, such as student health clinics, labor and delivery suites, and emergency rooms. The cost-effectiveness offered by these immunoassays will influence segment growth over the forecast period. 
• Molecular diagnostics segment is likely to witness the highest growth over the forecast period, driven by the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics, increasing R&D funding, growing awareness of the early detection of infectious diseases, and the increasing use of POC diagnostic tests.
• Microfluidic based point-of-care testing provides prompt results and also improves disease detection and diagnosis with the help of small sample volumes. 

By End Users: Global Point of Care Testing Market & Forecast - Key Takeaways

• Based on end users, the point-of-care testing market is segmented into Hospitals, Clinics, Laboratories, Home Care and Assisted Living Healthcare Facilities. 
• Hospitals held the majority of the point-of-care testing market, followed by Clinics. Increase in the prevalence of chronic conditions such as cancer and cardiovascular diseases that require proper monitoring and prefer minimally invasive procedures are carried out in hospitals and clinics. The use of point of care testing devices in clinics is expanding at a significant pace. A significant number of Clinical Laboratory Improvement Amendments (CLIA)-waived tests are implemented within clinics for diagnosis of a diverse range of disorders. 
• The home care segment is expected to grow at the highest rate over the forecast period driven by increasing preference for home and remote monitoring and rising demand for rapid tests among home care users. The availability of cost-effective and user-friendly alternatives for disease management will stimulate the segmental growth over the forecast timeframe.

By Region: Global Point of Care Testing Market & Forecast - Key Takeaways

• North America captured the highest share of the global point of care testing market in 2023. This can be attributed to the rising prevalence of chronic disorders and infectious diseases, which need portable and rapid diagnosis, an increasing number of product approvals, and rising government initiatives to support the adoption of POCT in this region. 
• Europe held second highest share of the global point of care testing market. The growth would be supported by the launch of new products, innovative technological revolution, rising prevalence of chronic disorders and infectious diseases, and increase in reliability of POCT products by home patients & institutional buyers. 
• Asia-Pacific point-of-care testing market is expected to grow at a lucrative rate over the forecast period, driven by four major factors namely the growing geriatric population base in countries such as Japan and China, rising prevalence of target diseases, increasing demand for home healthcare and the introduction of new products enabled with advanced technologies. 

This 308 Page report with 73 Figures and 12 Tables has been analyzed from 10 View Points:

1) Global - Point of Care Testing Market & Forecast (2015 - 2031)
2) Global - Point of Care Testing Market Share and Forecast (2015 - 2031)
3) By Diagnostics Segment - Global Point of Care Testing Market & Forecast (2015 - 2031)
4) By Mode - Global Point of Care Testing Market & Forecast (2015 - 2031)
5) By Platform - Global Point of Care Testing Market & Forecast (2015 - 2031)
6) By End Users - Global Point of Care Testing Market & Forecast (2015 - 2031)
7) By Region - Global Point of Care Testing Market & Forecast (2015 - 2031)
8) Global Point of Care Testing Market - Recent Developments 
9) Global Point of Care Testing Market - 104 Company Profiles 
10) Global Point of Care Testing Market - Growth Drivers & Challenges

By Diagnostics Segment - Global Point of Care Testing Market & Forecast 

1. Blood Glucose Testing
2. Cardiac Marker Testing
3. Lipid Panel/Cholesterol Testing
4. Coagulation Testing
5. Infectious Disease Testing
6. Urinalysis Testing
7. Drug of Abuse Testing
8. Fecal Occult Blood Testing
9. Pregnancy & Fertility Testing
10. Tumor Marker Testing
11. Critical Care Testing
12. HbA1c Testing 
13. Clinical Chemistry Testing
14. Bilirubin Testing
15. Hematology Testing

By Mode - Global Point of Care Testing Market & Forecast 

• Prescription-based Testing 
• TC-based Testing

By Platform - Global Point of Care Testing Market & Forecast 

• Lateral Flow Assays
• Immunoassays
• Microfluidics
• Dipsticks
• Molecular Diagnostics
• Others

By End Users - Global Point of Care Testing Market & Forecast

1. Hospitals
2. Clinics
3. Laboratories
4. Assisted Living Healthcare Facilities
5. Home Care

By Region - Global Point of Care Testing Market & Forecast

1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa

Global Point of Care Testing Market - 104 Company Profiles

1. Abbott Laboratories 
2. Siemens Healthineers 
3. Roche Diagnostics 
4. Quest Diagnostics 
5. Becton, Dickinson and Company 
6. ACON Laboratories 
7. Abaxis, Inc 
8. Abingdon Health, Ltd 
9. Access Bio, Inc. 
10. AccuBioTech Co, Ltd. 
11. Akers Biosciences, Inc. 
12. Alfa Scientific Designs, Inc 
13. American Bio Medica Corporation 
14. AmniSure International 
15. Aquila Diagnostic Systems, Inc 
16. ARKRAY Inc 
17. Artron Laboratories Inc. 
18. Ascensia Diabetes Care Holdings AG 
19. Immune IQ (Formerly Ativa) 
20. Atlas Link Biotech Co., Ltd 
21. Audit Diagnostics 
22. Augurix Diagnostics 
23. Autobio Diagnostics Co., Ltd 
24. Axxin 
25. Beckman Coulter, Inc 
26. Bhat Bio-Tech India Private Ltd. 
27. bioLytical Laboratories 
28. BioMedomics, Inc 
29. Biomerica, Inc. 
30. bioMerieux SA 
31. Biophor Diagnostics, Inc 
32. Bio-Rad Laboratories Inc. 
33. Bioscan Screening Systems, Inc. 
34. Biosensia Ltd. 
35. BTNX Inc. 
36. Boditech Med Inc 
37. Xiamen Boson Biotech Co. Ltd 
38. Calypte Biomedical Corporation 
39. Cepheid, Inc 
40. Chembio Diagnostic Systems, Inc. (Acquired by Biosynex SA) 
41. Clarity Diagnostics, LLC 
42. Confirm Biosciences 
43. CTK Biotech, Inc. 
44. Danaher Corporation 
45. Dexcom, Inc 
46. DIALAB GmbH 
47. DiaSys Diagnostic Systems GmbH 
48. Diazyme Laboratories, Inc. 
49. DNA Electronics Ltd. (DNAe) 
50. EKF Diagnostics Holdings plc 
51. ELITechGroup, Inc. 
52. Eurolyser Diagnostica GmbH 
53. Exact Sciences Corporation 
54. Exalenz Bioscience Ltd. (Acquired by Meridian Bioscience, Inc.) 
55. Genedrive plc 
56. GeTein BioMedical, Inc. 
57. Helena Laboratories 
58. Hemosure, Inc. 
59. Immunostics, Inc. 
60. Instrumentation Laboratory 
61. JAL Innovation PTE LTD 
62. Jant Pharmacal Corporation 
63. LamdaGen Corporation 
64. LifeScan, Inc 
65. LifeSign, LLC 
66. MBio Diagnostics, Inc (Now LightDeck Diagnostics) 
67. Medix Biochemica 
68. Medtronic, Inc 
69. A. Menarini Diagnostics S.R.L. 
70. Meridian Bioscience, Inc 
71. Nano-Ditech Corporation 
72. Noble Medical, Inc 
73. Nova Biomedical, Corp. 
74. Oasis Diagnostics Corporation 
75. OPTI Medical Systems, Inc 
76. OPKO Health, Inc 
77. OraSure Technologies, Inc 
78. Polymed Therapeutics Inc. 
79. Preventis GmbH 
80. Princeton Biomeditech Corporation 
81. QuantuMDx Group Limited 
82. Radiometer Medical A/S 
83. Response Biomedical Corp 
84. Reszon Diagnostics International Sdn. Bhd. 
85. Samsung Healthcare 
86. Savyon Diagnostics 
87. Sekisui Diagnostics LLC 
88. Siloam Biosciences, Inc 
89. Sysmex Corporation 
90. TECHLAB, Inc. 
91. Teco Diagnostics 
92. Trinity Biotech PLC 
93. Trividia Health 
94. Tulip Diagnostics Ltd 
95. Veredus Laboratories PTE Ltd 
96. Vircell 
97. WAMA Diagnostica 
98. Wave 80 Biosciences 
99. Werfen
100. Quidel Corporation
101. Thermo Fisher Scientific
102. Mesa Biotech Inc
103. GeneSTAT Molecular Diagnostics, LLC
104. Biocartis Group NV 

Data Source

The publisher employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from the Proprietary Information Database, Primary and Secondary Research Methodologies, and In-house analysis by a dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interviews, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine, and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.